Glioblastoma Biomarkers Detection
Glioblastoma (GBM) is an aggressive and lethal form of brain cancer that originates in astrocytes, the supportive cells in the nervous system. Due to its aggressive nature, early detection and accurate diagnosis are critical for effective treatment and improved patient outcomes. Traditional diagnostic methods, such as imaging and tissue biopsies, have limitations, particularly in providing real-time information and differentiating treatment effects from tumor progression. As a result, there is a growing interest in identifying reliable biomarkers for GBM to aid in diagnosis, prognosis, and treatment monitoring. Types of Biomarkers Biomarkers for glioblastoma can be broadly categorized into molecular and biofluid-based biomarkers: 1. Molecular Biomarkers: These include genetic and protein markers that can indicate the presence or progression of GBM. Common molecular biomarkers include mutations in the IDH1/2 genes, methylation of the MGMT promoter, and alterations in the EGFR and TERT…


